Exploring the cellular landscape of hip osteoarthritis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to investigate the complex etiology and cellular landscape of hip osteoarthritis using advanced techniques such as single-cell RNA sequencing and spatial omics. The researchers will analyze cell populations in synovial tissues and blood samples from osteoarthritis patients, comparing them to non-arthritic controls. The study also seeks to identify potential biomarkers for osteoarthritis and differentiate OA endotypes. Additionally, a sub-study will compare the cellular characteristics of osteoarthritis and rheumatoid arthritis patients undergoing total hip arthroplasty.

Why it matters

Who can join: the full rules

Inclusion Criteria for the main (OA) study:

Cases: Adult patients with osteoarthritis in the hip joint and who are going through an elective total hip arthroplasty.

Controls: Non-arthritis adult patients who are going through a trauma-based emergency total hip arthroplasty.

\----

Inclusion Criteria for the Rheumatoid sub-study:

Adult patients with rheumatoid arthritis in the hip joint and who are going through an elective total hip arthroplasty.

\----

Exclusion Criteria:

* The body mass index must be below 35
* Age \< 18 or \> 74
* The OA patients may not have diabetes, rheumatoid arthritis (RA), or metabolic syndrome.

For the Rheumatoid sub-study, the exclusion criteria are the same as above except for the RA.

Where it's running

• Turku University Hospital
  Turku, Southwest Finland, Finland Recruiting
• Helsinki University Hospital
  Espoo, Uusimaa, Finland Recruiting
• PET-centre, University of Turku
  Turku, Southwest Finland, Finland Active not recruiting
• Turku Bioscience, University of Turku
  Turku, Southwest Finland, Finland Active not recruiting

Study contacts

• Principal investigator: Lea Mikkola, PhD — Turku Bioscience, University of Turku
• Study coordinator: Lea Mikkola, PhD
• Email: limikk@utu.fi
• Phone: +358404143300

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• GenAI-assisted RA bone erosion risk and DMARD choice

  This study tests whether GenAI-based decision support can help doctors assess rheumatoid arthritis bone erosion risk and pick DMARDs for newly diagnosed inpatients.

  Recruiting Guang'anmen Hospital of China Academy of Chinese Medical Sciences · Beijing, Beijing Municipality · NCT07914907

• Pain patterns in rheumatic diseases: see if pain works differently in patients and healthy people

  This observational study tests how pain is experienced and measured in people with rheumatic diseases compared with healthy volunteers.

  Recruiting National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07829497

• Collarless Actis hip stem for cementless hip replacement in Asian patients

  This study tests how well a collarless Actis hip stem works in adults undergoing primary hip replacement, focusing on outcomes over five years in an East Asian population.

  Recruiting Seoul National University Bundang Hospital · Seongnam-si, Gyeonggi-do · NCT07828080

• Telitacicept for difficult-to-treat rheumatoid arthritis

  This study tests whether adding telitacicept to standard therapy helps adults with hard-to-treat rheumatoid arthritis see better control of their symptoms.

  Recruiting Phase 2 Peking University People's Hospital · Hefei, Anhui and 46 other locations · NCT07796516

• PTC844 in people with active rheumatoid arthritis

  This study tests whether PTC844 is safe and how it behaves in the body compared with placebo for people with active rheumatoid arthritis.

  Recruiting at 6 sites Phase 2 PTC Therapeutics · Chandler, Arizona and 25 other locations · NCT07779616

• First-in-human test of CND319 in healthy people and people with rheumatic diseases

  This early study tests whether CND319 is safe and tolerable and whether it shows any signs of activity in healthy adults and in people with rheumatoid arthritis or Sjogren's syndrome.

  Recruiting Phase 1 Candid Therapeutics · Melbourne, Victoria · NCT07712939

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.